IOL CHEMICALS & PHARM. | LYKA LABS | IOL CHEMICALS & PHARM./ LYKA LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 13.3 | -121.3 | - | View Chart |
P/BV | x | 1.5 | 15.3 | 9.9% | View Chart |
Dividend Yield | % | 1.0 | 0.0 | - |
IOL CHEMICALS & PHARM. LYKA LABS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
IOL CHEMICALS & PHARM. Mar-23 |
LYKA LABS Mar-23 |
IOL CHEMICALS & PHARM./ LYKA LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 537 | 202 | 265.4% | |
Low | Rs | 272 | 100 | 272.7% | |
Sales per share (Unadj.) | Rs | 377.6 | 30.3 | 1,245.2% | |
Earnings per share (Unadj.) | Rs | 23.7 | -4.3 | -553.0% | |
Cash flow per share (Unadj.) | Rs | 31.6 | 0.3 | 9,735.0% | |
Dividends per share (Unadj.) | Rs | 4.00 | 0 | - | |
Avg Dividend yield | % | 1.0 | 0 | - | |
Book value per share (Unadj.) | Rs | 256.8 | 9.1 | 2,814.5% | |
Shares outstanding (eoy) | m | 58.71 | 30.69 | 191.3% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.1 | 5.0 | 21.5% | |
Avg P/E ratio | x | 17.1 | -35.2 | -48.4% | |
P/CF ratio (eoy) | x | 12.8 | 465.7 | 2.8% | |
Price / Book Value ratio | x | 1.6 | 16.5 | 9.5% | |
Dividend payout | % | 16.9 | 0 | - | |
Avg Mkt Cap | Rs m | 23,743 | 4,634 | 512.4% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 1,682 | 186 | 904.1% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 22,171 | 931 | 2,382.1% | |
Other income | Rs m | 256 | 34 | 753.0% | |
Total revenues | Rs m | 22,427 | 965 | 2,324.7% | |
Gross profit | Rs m | 2,257 | 94 | 2,389.1% | |
Depreciation | Rs m | 462 | 141 | 326.3% | |
Interest | Rs m | 165 | 119 | 138.8% | |
Profit before tax | Rs m | 1,887 | -132 | -1,432.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 495 | 0 | -260,578.9% | |
Profit after tax | Rs m | 1,391 | -132 | -1,057.9% | |
Gross profit margin | % | 10.2 | 10.1 | 100.3% | |
Effective tax rate | % | 26.2 | 0.1 | 18,484.7% | |
Net profit margin | % | 6.3 | -14.1 | -44.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 9,667 | 442 | 2,186.8% | |
Current liabilities | Rs m | 5,025 | 326 | 1,541.6% | |
Net working cap to sales | % | 20.9 | 12.5 | 167.9% | |
Current ratio | x | 1.9 | 1.4 | 141.9% | |
Inventory Days | Days | 43 | 90 | 48.0% | |
Debtors Days | Days | 8 | 789 | 1.1% | |
Net fixed assets | Rs m | 11,017 | 1,073 | 1,026.6% | |
Share capital | Rs m | 587 | 307 | 191.3% | |
"Free" reserves | Rs m | 14,490 | -27 | -53,926.7% | |
Net worth | Rs m | 15,077 | 280 | 5,384.1% | |
Long term debt | Rs m | 0 | 638 | 0.0% | |
Total assets | Rs m | 20,684 | 1,515 | 1,365.1% | |
Interest coverage | x | 12.5 | -0.1 | -11,362.9% | |
Debt to equity ratio | x | 0 | 2.3 | 0.0% | |
Sales to assets ratio | x | 1.1 | 0.6 | 174.5% | |
Return on assets | % | 7.5 | -0.8 | -889.1% | |
Return on equity | % | 9.2 | -47.0 | -19.6% | |
Return on capital | % | 13.6 | -1.4 | -960.0% | |
Exports to sales | % | 26.7 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | 5,930 | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 5,930 | 0 | - | |
Fx outflow | Rs m | 6,052 | 0 | - | |
Net fx | Rs m | -122 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,223 | 90 | 1,365.7% | |
From Investments | Rs m | -1,200 | 74 | -1,632.7% | |
From Financial Activity | Rs m | -41 | -216 | 19.0% | |
Net Cashflow | Rs m | -18 | -53 | 34.5% |
Indian Promoters | % | 48.2 | 54.8 | 87.9% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 1.7 | 1.0 | 173.5% | |
FIIs | % | 1.4 | 0.2 | 823.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 51.8 | 45.2 | 114.6% | |
Shareholders | 130,003 | 25,717 | 505.5% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare IOL CHEMICALS & PHARM. With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | IOL CHEMICALS & PHARM. | LYKA LABS | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.54% | 3.03% | -1.23% |
1-Month | 7.66% | 17.50% | 1.07% |
1-Year | -1.73% | 15.87% | 50.86% |
3-Year CAGR | -11.66% | 66.40% | 14.38% |
5-Year CAGR | 15.36% | 34.15% | 19.01% |
* Compound Annual Growth Rate
Here are more details on the IOL CHEMICALS & PHARM. share price and the LYKA LABS share price.
Moving on to shareholding structures...
The promoters of IOL CHEMICALS & PHARM. hold a 48.2% stake in the company. In case of LYKA LABS the stake stands at 54.8%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of IOL CHEMICALS & PHARM. and the shareholding pattern of LYKA LABS.
Finally, a word on dividends...
In the most recent financial year, IOL CHEMICALS & PHARM. paid a dividend of Rs 4.0 per share. This amounted to a Dividend Payout ratio of 16.9%.
LYKA LABS paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of IOL CHEMICALS & PHARM., and the dividend history of LYKA LABS.
For a sector overview, read our pharmaceuticals sector report.
It was indeed a volatile trading session for Indian share markets yesterday.